Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTI.L Regulatory News (CTI)

  • There is currently no data for CTI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Requisition Notice

29 Sep 2020 13:14

RNS Number : 4695A
Cathay International Holdings Ld
29 September 2020
 

Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR).

Cathay International Holdings Limited

("Cathay" or the "Company")

Requisition Notice Received by the Company

Hong Kong, 29 September 2020 - Cathay International Holdings Ltd. (LSE: CTI.L), an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"), announces that on 28 September 2020 it received a notice from Circle Finance Limited and Mega Worldwide Services Limited, the holders of in aggregate 1,373,940,837 Common Shares of USD 0.01 each ("Common Shares") and 8,249,276 A Shares of USD 0.01 each ("A Shares" and together with the Common Shares, the "the "Shares"), requisitioning a general meeting of the Company's shareholders (the "Requisition Notice"). The Requisition Notice proposes resolutions (i): (a) to approve of the cancellation of the Company's listing (i.e. admission of its Common Shares to the official list of the FCA), and the cancellation of the admission of the Common Shares to trading on the main market of the London Stock Exchange, (the "Listing Cancellation"); and (b) to direct the directors of the Company (the "Directors") to take any and all actions required or reasonably necessary to effect the Listing Cancellation, and to make all associated notifications and announcements as may be reasonably required to effect the Listing Cancellation; and (ii) subject to the approval of resolution (i), to approve the adoption of a set of amended and restated bye-laws of the Company. In addition to the Requisition Notice, Circle Finance Limited has provided a letter of undertaking ("Letter of Undertaking"), setting out an irrevocable commitment, which is subject to the Listing Cancellation being approved by shareholders of the Company and becoming effective, to fund the payment for an exit opportunity available for all shareholders of the Company who wish to offer to sell their Shares for cash at a maximum price of 1.7p per Share on certain terms and conditions.

The board of Directors is considering the contents of the Requisition Notice and Letter of Undertaking and will make further detailed announcements as appropriate.

Shareholders are advised that there is no certainty that the proposed Listing Cancellation will proceed or that the Letter of Undertaking will result in an exit opportunity being crystalised, or to the timing of such, and therefore to take precaution in dealing in the Company's shares.

 

-Ends-

 

For further enquiries, please contact:

 

Cathay International Holdings Limited

Eric Siu (Finance Director)

Patrick Sung (Director and Controller)

 

 

Tel: +852 2828 9289

SPARK Advisory Partners Limited (financial adviser)

Andrew Emmott / James Keeshan

 

Tel: +44 (0) 20 3368 3555

 

About Cathay

 

Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on investment opportunities in the growing domestic demand for high quality healthcare products in the PRC and build portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a track record of identifying investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.

 

The Group employs approximately 1,300 people across the PRC, including over 20 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCLKLFLBKLFBBL
Date   Source Headline
2nd Apr 20157:00 amRNSGrant of Share Options
30th Mar 20157:35 amRNSRepeat of Annual Results Announcement RNS 7096I
27th Mar 201512:14 pmRNSAnnual Results for the Year Ended 31 December 2014
25th Mar 20157:00 amRNSHolding(s) in Company
12th Mar 20157:00 amRNSNotice of Annual Results 2014
5th Jan 20159:16 amRNSLansen's New Distribution Agreement
18th Dec 20148:36 amRNSLansen and Haotian Renew Supply Agreement
29th Aug 20149:26 amRNSInterim results for six months ended 30 June 2014
19th Aug 20147:00 amRNSNotice of Interim Results 2014
23rd May 201410:38 amRNSResult of AGM
19th May 20147:00 amRNSInterim Management Statement
7th Apr 20148:58 amRNSGrant of Share Options
31st Mar 20147:00 amRNSAcquisition of Sicorten Plus in the PRC
28th Mar 20148:47 amRNSAnnual Results for the Year Ended 31 December 2013
14th Mar 20147:00 amRNSNotice of Annual Results
19th Nov 20137:00 amRNSInterim Management Statement
15th Oct 201310:24 amRNSTransfer of Misoprostol Development Project
3rd Sep 20131:31 pmRNSLansen and Haotian Sign Supply Agreement
30th Aug 20139:42 amRNSInterim Results for the six months ended June 2013
19th Aug 20139:24 amRNSNotice of Interim Results
21st May 20137:00 amRNSResults of Annual General Meeting
16th May 20137:00 amRNSInterim Management Statement
11th Apr 20137:00 amRNSAnnual Report and Accounts
4th Apr 20139:03 amRNSGrant of Share Options
27th Mar 20138:30 amRNSAnnual Results for the Year Ended 31 December 2012
14th Mar 20139:33 amRNSNotice of Annual Results 2012
6th Mar 20138:30 amRNSCathay's subsidiary Lansen board change
26th Feb 201310:37 amRNSTR-1: Notification of Major Interest in Shares
23rd Nov 20128:55 amRNS1.5% holding in Zhejiang Starry Pharmaceutical Co.
19th Nov 20127:00 amRNSInterim Management Statement
29th Aug 201212:15 pmRNSTotal Voting Rights and Share Capital
29th Aug 20129:23 amRNSInterim results
15th Aug 20127:00 amRNSNotice of Interim Results
25th May 201211:26 amRNSResult of AGM
21st May 20127:00 amRNSAnnual Information Update
17th May 20127:00 amRNSInterim Management Statement
10th May 20127:00 amRNSLicense for collagen injectable filler
20th Apr 20129:15 amRNSAnnual Report and Accounts
3rd Apr 201210:50 amRNSGrant of Share Options
29th Mar 20129:32 amRNSAnnual Results for the Year Ended 31 December 2011
19th Mar 201210:00 amRNSNotification of Annual Results
27th Feb 20129:43 amRNSLansen Received Technology Endorsement
9th Jan 20129:00 amRNSLansen signs exclusive agreement
18th Nov 20117:00 amRNSInterim Management Statement
26th Oct 20119:47 amRNSLansen signs exclusive agreement with Ethypharm
25th Aug 20115:00 pmRNSInterim Results
15th Aug 201111:12 amRNSNotice of Interim Results
20th May 20117:00 amRNSAnnual Information Update
19th May 20117:00 amRNSInterim Management Statement
6th Apr 20117:00 amRNSTotal Voting Rights and Share Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.